Pharmaceuticals

Global End Stage Renal Disease (ESRD) Drug Market Valuation and Growth Prospects: $262.76 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the end stage renal disease (esrd) drug market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The End Stage Renal Disease (ESRD) Drug Market Size?

The market size for end stage renal disease (esrd) drugs has seen considerable expansion in recent years. Forecasts indicate its increase from $131.41 billion in 2024 to $148.55 billion by 2025, achieving a compound annual growth rate (CAGR) of 13.0%. The expansion observed in prior periods is attributable to a rising incidence of end stage renal disease, an expanding elderly demographic, better access to healthcare services, government-led initiatives and policies, and the wider acceptance of renal replacement therapies.

The end stage renal disease (esrd) drug market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $262.76 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 15.3%. This projected growth is driven by factors such as novel therapies and drug breakthroughs, increased spending on healthcare, the escalating global prevalence of chronic kidney diseases, tailored medicine strategies, government support, and faster approval processes. Significant trends expected during this period involve a rise in end stage renal disease cases, improvements in treatment options, a greater focus on personalized medicine, the creation of combination treatments, and the integration of technology into healthcare.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What Core Market Drivers Are Expanding The End Stage Renal Disease (ESRD) Drug Industry?

The end-stage renal disease (ESRD) drug market is anticipated to expand due to an increase in obesity and diabetes cases. Obesity is characterized by an unhealthy accumulation or excess of body fat that poses a health risk. Conversely, diabetes refers to a long-term illness where the pancreas either fails to produce sufficient insulin or the body struggles to effectively use the insulin it makes. For individuals suffering from renal disease, interventions such as regulating fluid and electrolyte balances, controlling blood pressure, and removing waste products via dialysis can enhance overall health, potentially resulting in weight loss and better management of blood sugar levels. As an illustration, World Obesity, a US-based membership organization focused on obesity study and management, reported in March 2022 that the global count of obese individuals is projected to reach 892 million by 2025, further climbing to 1,025 million by 2030. Moreover, the National Health Service, the UK’s publicly funded healthcare system, stated in February 2023 that an estimated 5.5 million people in the UK could have diabetes by 2030, affecting almost 9% of the population. Consequently, the increasing prevalence of obesity and diabetes is set to be a key impetus for the end-stage renal disease (ESRD) drug market.

What Segment Insights Are Highlighted In The End Stage Renal Disease (ESRD) Drug Market Report?

The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

Which Notable Trends Are Transforming The End Stage Renal Disease (ESRD) Drug Market Outlook?

Product innovations represent a key trend gaining traction in the end-stage renal disease (ESRD) drug market. Major companies operating within the end-stage renal disease (ESRD) drug market are concentrating on developing novel solutions to sustain their presence. For instance, in April 2022, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology firm, announced the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), intended for the potential treatment of patients with chronic kidney disease anemia (CKD). This new product draws upon unique Nobel prize-winning scientific discoveries that demonstrated how cells perceive and adapt to oxygen availability.

Which Firms Are Driving Innovation Within The End Stage Renal Disease (ESRD) Drug Market?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

What Regional Trends Are Shaping Growth In The End Stage Renal Disease (ESRD) Drug Market?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

Browse Through More Reports Similar to the Global End Stage Renal Disease (ESRD) Drug Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795